^
    Back
    Association details:
    Biomarker:CD276 expression
    Cancer:Head and Neck Cancer
    Drug:vobramitamab duocarmazine (MGC018) (DNA replication inhibitor, B7-H3-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer

    Published date:
    09/23/2020
    Excerpt:
    ...antitumor activity was observed toward patient-derived xenograft models of breast, prostate and head and neck cancer displaying heterogeneous expression of B7-H3.
    DOI:
    10.1158/1535-7163.MCT-20-0116